{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:00:42Z","timestamp":1787014842578,"version":"build-2736575974"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T00:00:00Z","timestamp":1210723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p>\n                    <jats:bold>Objectives.\u2014<\/jats:bold>\n                    To assess the efficacy and safety of almotriptan 6.25\u2003mg, 12.5\u2003mg, and 25\u2003mg vs placebo for acute migraine treatment in adolescents.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and Methods.\u2014<\/jats:bold>\n                    In this double\u2010blind, placebo\u2010controlled, parallel\u2010group, multicenter trial, 866 patients aged 12 to 17\u2003years with a &gt;1\u2003year history of migraine (per International Headache Society criteria) were randomized to treat one migraine headache with almotriptan 6.25\u2003mg, 12.5\u2003mg, 25\u2003mg, or placebo. The primary efficacy endpoint was headache pain relief 2\u2003hours after dosing, adjusted for baseline severity, with absence of nausea, photophobia, and phonophobia 2\u2003hours after dosing as coprimary endpoints.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    The 2\u2010hour pain\u2010relief rate was significantly higher with almotriptan 25\u2003mg compared with placebo (66.7% vs 55.3%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u2003.022). The incidence of nausea, photophobia, and phonophobia at 2\u2003hours (adjusted for baseline pain intensity) for the almotriptan 25\u2003mg and placebo groups was not significantly different. The 2\u2010hour pain\u2010relief rates (unadjusted) were significantly higher with almotriptan 6.25\u2003mg (71.8%), 12.5\u2003mg (72.9%), and 25\u2003mg (66.7%) than with placebo (55.3%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u2003.001,\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.001, and\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u2003.028, respectively). Rates for sustained pain relief also were significantly greater with almotriptan 6.25\u2003mg (67.2%), 12.5\u2003mg (66.9%), and 25\u2003mg (64.5%) than with placebo group (52.4%),\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.01 for the 6.25\u2010 and 12.5\u2010mg doses and\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u2003.05 for the 25\u2010mg dose. Age group subanalysis demonstrated significantly greater 2\u2010hour pain\u2010relief rates with all 3 doses of almotriptan compared with placebo for patients aged 15 to 17\u2003years, a significantly lower incidence of photophobia and phonophobia at 2\u2003hours with almotriptan 12.5\u2003mg compared with placebo for patients aged 15 to 17\u2003years, and a significantly lower incidence of photophobia with almotriptan 12.5\u2003mg compared with placebo for those aged 12 to 14\u2003years. Almotriptan treatment was well tolerated, with the most common adverse events (&gt;2%) of nausea, dizziness, and somnolence.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    Oral almotriptan was efficacious for relieving migraine headache pain in adolescents, with the 12.5\u2010mg dose associated with the most favorable efficacy profile with respect to relieving headache pain and associated symptoms of migraine (photophobia and phonophobia). Almotriptan treatment was well tolerated in this adolescent population.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2008.01138.x","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T11:38:30Z","timestamp":1210765110000},"page":"1326-1336","source":"Crossref","is-referenced-by-count":97,"title":["Efficacy and Tolerability of Almotriptan in Adolescents: A Randomized, Double\u2010Blind, Placebo\u2010Controlled Trial"],"prefix":"10.1111","volume":"48","author":[{"given":"Steven L.","family":"Linder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninan T.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Ishkanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,3]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.309.6957.765"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116014"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.1999.3907494.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1993.hed3301029.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.1.e1"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06711-3"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02013.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2004.04171.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00313.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00755.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000231138.18629.d5"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000238179.79888.44"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.106.5.989"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00339.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0085"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000115105.05966.A7"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1507"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.01010.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05031.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.58.9.1479"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000147332.41993.90"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2742"},{"issue":"7","key":"e_1_2_7_24_2","first-page":"1","article-title":"Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache classification committee of the International Headache Society","volume":"8","author":"Headache Classification","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-007-0197-1"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.00260.x"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/1073858404263960"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000085039"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.4.1100"},{"key":"e_1_2_7_30_2","first-page":"233","article-title":"Nimesulide and acetaminophen for the treatment of juvenile migraine: A study for comparison of efficacy, safety, and tolerability","volume":"12","author":"Soriani S","year":"2001","journal-title":"Headache Q"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02180.x"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2008.01138.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2008.01138.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:35:40Z","timestamp":1762083340000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2008.01138.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1111\/j.1526-4610.2008.01138.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01138.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}